Onconetix Statistics
Onconetix (J4T2) Stock Statistics & Valuation Metrics
Total Valuation
Onconetix has a market cap or net worth of EUR 1.84M. The enterprise value is -EUR 3.09T.
- Market Cap
- EUR 1.84M
- Enterprise Value
- -EUR 3.09T
Share Statistics
Onconetix has 588,677 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 588,677
- Owned by Insiders
- 5.72%
- Owned by Institutions
- 3.85%
Financial Efficiency
Onconetix’s return on equity (ROE) is -0.89 and return on invested capital (ROIC) is -40.12%.
- Return on Equity (ROE)
- -0.89
- Return on Assets (ROA)
- -0.56
- Return on Invested Capital (ROIC)
- -40.12%
- Return on Capital Employed (ROCE)
- -0.40
- Revenue Per Employee
- 407.69K
- Profits Per Employee
- -7.02M
- Employee Count
- 2
- Asset Turnover
- 0.03
- Inventory Turnover
- 1.22
Valuation Ratios
The current PE Ratio of Onconetix is -0.04. Onconetix’s PEG ratio is -0.00.
- PE Ratio
- -0.04
- PS Ratio
- 1.93
- PB Ratio
- 0.06
- Price to FCF
- -0.12
- Price to Operating Cash Flow
- -0.08
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Onconetix had revenue of 815.37K and earned -14.03M in profits. Earnings per share was -47.30.
- Revenue
- 815.37K
- Gross Profit
- 632.91K
- Operating Income
- -6.34M
- Pretax Income
- -14.03M
- Net Income
- -14.03M
- EBITDA
- -13.27M
- Earnings Per Share (EPS)
- -47.30
Cash Flow
In the last 12 months, operating cash flow was -10.31M and capital expenditures 3, giving a free cash flow of -10.31M billion.
- Operating Cash Flow
- -10.31M
- Free Cash Flow
- -10.31M
- Free Cash Flow per Share
- -45.96
Dividends & Yields
Onconetix pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -876.80%
- Earnings Yield
- -1386.05%
Stock Price Statistics
- Beta
- 0.00
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 119850.00
- 200-Day Moving Average
- 119850.00
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
Onconetix as a current ratio of 0.66, with Debt / Equity ratio of 0.31%
- Current Ratio
- 0.66
- Quick Ratio
- 0.65
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.39
- Interest Coverage Ratio
- -8.45
Taxes
In the past 12 months, Onconetix has paid 525 in taxes.
- Income Tax
- 525
- Effective Tax Rate
- -0.00
Enterprise Valuation
Onconetix EV to EBITDA ratio is 0.46, with an EV/FCF ratio of 0.44.
- EV to Sales
- -7.09
- EV to EBITDA
- 0.46
- EV to Free Cash Flow
- 0.44
- EV to Operating Cash Flow
- 0.44
Balance Sheet
Onconetix has EUR 5.94M in cash and marketable securities with EUR 187.13K in debt, giving a net cash position of EUR 5.76M billion.
- Cash & Marketable Securities
- EUR 5.94M
- Total Debt
- EUR 187.13K
- Net Cash
- EUR 5.76M
- Net Cash Per Share
- EUR 9.78
- Tangible Book Value Per Share
- EUR 17.17
Margins
Gross margin is 80.40%, with operating margin of -1265.55%, and net profit margin of -1578.79%.
- Gross Margin
- 80.40%
- Operating Margin
- -1265.55%
- Pretax Margin
- -1578.71%
- Net Profit Margin
- -1578.79%
- EBITDA Margin
- -1528.27%
- EBIT Margin
- -1530.56%
Analyst Forecast
The average price target for Onconetix is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -51.33%
- EPS Growth Forecast
- 99.22%
